View in EDS

Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.

Saved in:
Bibliographic Details
Title: Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.
Authors: Salamat-Miller N; Process Development, Formulation Development, Takeda, Lexington, MA, USA. Electronic address: nazila.miller@takeda.com., Qu W; BioAnalytix, Cambridge, MA, USA., Chadwick JS; BioAnalytix, Cambridge, MA, USA., McPherson C; Department of Pediatrics, Washington University, St. Louis, MO, USA., Salinas PA; Analytical Development-Biologics-US, Takeda, Lexington, MA, USA., Turner M; Institute of Translational Medicine, University of Liverpool, Liverpool, UK., Wang D; BioAnalytix, Cambridge, MA, USA., Barton N; Global Clinical Development, Rare Metabolic Diseases, Takeda, Lexington, MA, USA.
Source: Journal of pharmaceutical sciences [J Pharm Sci] 2022 May; Vol. 111 (5), pp. 1486-1496. Date of Electronic Publication: 2021 Oct 28.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 2985195R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6017 (Electronic) Linking ISSN: 00223549 NLM ISO Abbreviation: J Pharm Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34717953
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Salamat-Miller+N%22">Salamat-Miller N</searchLink>; Process Development, Formulation Development, Takeda, Lexington, MA, USA. Electronic address: nazila.miller@takeda.com.<br /><searchLink fieldCode="AU" term="%22Qu+W%22">Qu W</searchLink>; BioAnalytix, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Chadwick+JS%22">Chadwick JS</searchLink>; BioAnalytix, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22McPherson+C%22">McPherson C</searchLink>; Department of Pediatrics, Washington University, St. Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Salinas+PA%22">Salinas PA</searchLink>; Analytical Development-Biologics-US, Takeda, Lexington, MA, USA.<br /><searchLink fieldCode="AU" term="%22Turner+M%22">Turner M</searchLink>; Institute of Translational Medicine, University of Liverpool, Liverpool, UK.<br /><searchLink fieldCode="AU" term="%22Wang+D%22">Wang D</searchLink>; BioAnalytix, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Barton+N%22">Barton N</searchLink>; Global Clinical Development, Rare Metabolic Diseases, Takeda, Lexington, MA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985195R%22">Journal of pharmaceutical sciences</searchLink> [J Pharm Sci] 2022 May; Vol. 111 (5), pp. 1486-1496. <i>Date of Electronic Publication: </i>2021 Oct 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>2985195R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1520-6017 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200223549%22">00223549 </searchLink><i>NLM ISO Abbreviation: </i>J Pharm Sci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34717953
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.xphs.2021.10.027
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1486
    Titles:
      – TitleFull: Development of Protein-Specific Analytical Methodologies to Evaluate Compatibility of Recombinant Human (rh)IGF-1/rhIGFBP-3 with Intravenous Medications Co-Administered to Neonates.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Salamat-Miller N
      – PersonEntity:
          Name:
            NameFull: Qu W
      – PersonEntity:
          Name:
            NameFull: Chadwick JS
      – PersonEntity:
          Name:
            NameFull: McPherson C
      – PersonEntity:
          Name:
            NameFull: Salinas PA
      – PersonEntity:
          Name:
            NameFull: Turner M
      – PersonEntity:
          Name:
            NameFull: Wang D
      – PersonEntity:
          Name:
            NameFull: Barton N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2022 May
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1520-6017
          Numbering:
            – Type: volume
              Value: 111
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Journal of pharmaceutical sciences
              Type: main
ResultId 1